The board of directors of China Traditional Chinese Medicine Co. Limited announced that based on the preliminary assessment by the company's management with reference to the unaudited consolidated management accounts of the group for the year ended December 31, 2014, the group is expected to record an increase of not less than 100% in consolidated net profit attributable to the shareholders for the year ended December 31, 2014 as compared with that of approximately RMB 198.5 million for the year ended December 31, 2013. The board considers that the improvement in the results of the group for the year ended December 31, 2014 as compared with that for 2013 was mainly attributable to (i) the consolidation of the full year financial results of Tongjitang Chinese Medicines Company (which was acquired by the company in October 2013) and its subsidiaries; and (ii) the organic growth of the group's traditional Chinese medicine and other pharmaceutical businesses.